High-altitude stem cell and bone marrow transplant registry on the Qinghai-Tibet Plateau

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

HALO-SCT is a prospective observational registry based at the Affiliated Hospital of Qinghai University that enrolls patients undergoing hematopoietic stem cell transplantation and their donors. The registry captures demographic, diagnostic, treatment, outcome, and health‑resource data and incorporates historical cases alongside ongoing prospective follow-up. Biospecimens including peripheral blood and bone marrow are collected at baseline and follow-up for future multi‑omics analyses. No experimental treatments are mandated and all clinical care follows routine practice while data are used to build long‑term research infrastructure and support collaborations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients diagnosed with hematologic diseases who are admitted to the HSCT center of Qinghai University Affiliated Hospital on or after September 1, 2023.
2. Planned or actual hematopoietic stem cell transplantation (HSCT).
3. Provision of signed informed consent.

Exclusion Criteria:

1. Inability to provide long-term follow-up data due to severe comorbidities or logistical reasons.
2. Substance abuse compromising adherence.
3. Any condition judged by investigators to jeopardize safety or compliance.

Where it's running

• Affiliated Hospital of Qinghai University
  Xining, Qinghai, China Recruiting

Study contacts

• Principal investigator: Hui Geng — Affiliated Hospital of Qinghai University
• Study coordinator: Yigeng CAO, MD,PhD
• Email: caoyigeng@ihcams.ac.cn
• Phone: +8618622477066

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term study of blood diseases in patients in China

  This study is trying to gather detailed information from patients in China with blood diseases like leukemia and multiple myeloma to better understand how these conditions affect their lives and treatment options.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT04645199

• Using Darzalex Faspro to lower antibody levels before stem cell transplant

  This study is testing if a new treatment called Darzalex Faspro can help lower harmful antibodies in adults so they can safely receive a stem cell transplant for blood cancers.

  Recruiting Early Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT06398457

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• Improving outcomes for stem cell transplant patients using an intervention website

  This study is testing if a special website can help adults with blood cancer feel better and improve their quality of life after a stem cell transplant compared to a regular educational website.

  Recruiting at 3 sites Northwestern University · Washington D.C., District of Columbia and 2 other locations · NCT06960993

• Comparing ATLG and ATG for immune recovery after allogeneic stem cell transplant

  This study will try using ATLG instead of ATG in adults receiving allogeneic stem cell transplants for blood cancers to see if immune recovery is faster and rates of viral infection or GVHD are lower.

  Recruiting Phase 2/3 Peking University First Hospital · Beijing · NCT06895538

• Using a NEWS early warning score to prompt ICU admission for adults receiving intensive chemotherapy or stem cell transplant

  This trial tests whether real-time monitoring with the NEWS early warning score and prompt ICU admission (NEWS ≥ 7) helps adults with leukemia, lymphoma, or multiple myeloma who are receiving intensive chemotherapy or a hematopoietic cell transplant.

  Recruiting at 9 sites University Hospital, Angers · Amiens and 9 other locations · NCT06409767

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.